FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897329076> ?p ?o ?g. }

• W2897329076 endingPage "S145" @default.
• W2897329076 startingPage "S144" @default.
• W2897329076 abstract "To prospectively observe CD8+ T-cell immunophenotypic changes in prostate cancer (PCa) patients treated with metastasis-directed stereotactic body radiation therapy (mdSBRT) and correlate these phenotypic changes with clinical outcomes. We prospectively analyzed peripheral blood mononuclear cells (PBMCs) that were isolated – before and at multiple time points after mdSBRT – from 37 patients enrolled between January 2013 and October 2014 with recurrent oligometastatic PCa (≤3 extracranial sites). Immunophenotyping was performed on isolated PBMCs using flow cytometry to identify subpopulations of circulating CD8+ T-cells including Tumor-Reactive (TTR; PD-1+CD11ahigh), Effector Memory (TEM; CCR7-CD45RA-), Central Memory (TCM; CCR7+CD45RA-), Effector (TEF; CCR7-CD45RA+), and Naïve (TN; CCR7+CD45RA+) T-cells. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and progression. Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis (NDM) was estimated considering death as a competing risk. Median follow-up was 39 months (IQR 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression at 3 years was 16.5% and for NDM at 3 years was 67.6%. Androgen deprivation therapy (ADT) was given concurrently with mdSBRT vs. delayed until additional progression for 19 (51%) and 18 (49%) patients, respectively. Concurrent ADT was protective against the risk of NDM (HR 0.44; 95% CI 0.20-0.96; p=0.039). Median time to NDM was 28 (IQR 5-41) vs. 8 (IQR 4-12) months for concurrent vs. delayed ADT, respectively. Seven out of 7 (100%) patients that continue to remain progression-free received concurrent ADT with mdSBRT. An increase in the TCM cell subpopulation between baseline and day 14 after mdSBRT was associated with the risk of death (HR 1.22; 95% CI 1.02-1.47; p=0.033). An increase in the TTR cell subpopulation between baseline and day 14 was protective against the risk of local progression (HR 0.80; 95% CI 0.65-0.98; p=0.032). Relative increases ≥1% in the TTR cell subpopulation between baseline and day 14 were associated with a non-significant protective effect against the risk of any progression, distant or local (HR 0.42; 0.17-1.01; p=0.052). Prospective CD8+ T-cell immunophenotyping before and after mdSBRT in patients with oligometastatic PCa provided insight into clinical outcomes. An increase in the TCM cell subpopulation was associated with the risk of death. An increase in the TTR cell subpopulation was protective against the risk of local progression. Concurrent ADT with mdSBRT was protective against the risk of NDM. This is the first report to show that an increase in the TTR cell subpopulation after mdSBRT is associated with PCa disease control, and has implications for combining mdSBRT and adoptive cell transfer therapies. Supported by NCI R01 CA200551." @default.
• W2897329076 created "2018-10-26" @default.
• W2897329076 creator A5012788874 @default.
• W2897329076 creator A5020227451 @default.
• W2897329076 creator A5023733267 @default.
• W2897329076 creator A5027176998 @default.
• W2897329076 creator A5030404850 @default.
• W2897329076 creator A5040197178 @default.
• W2897329076 creator A5040586351 @default.
• W2897329076 creator A5044668381 @default.
• W2897329076 creator A5046278307 @default.
• W2897329076 creator A5048628138 @default.
• W2897329076 creator A5054056429 @default.
• W2897329076 creator A5063163135 @default.
• W2897329076 creator A5071440718 @default.
• W2897329076 creator A5079400879 @default.
• W2897329076 creator A5083170859 @default.
• W2897329076 date "2018-11-01" @default.
• W2897329076 modified "2023-09-25" @default.
• W2897329076 title "Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy" @default.
• W2897329076 doi "https://doi.org/10.1016/j.ijrobp.2018.06.351" @default.
• W2897329076 hasPublicationYear "2018" @default.
• W2897329076 type Work @default.
• W2897329076 sameAs 2897329076 @default.
• W2897329076 citedByCount "0" @default.
• W2897329076 crossrefType "journal-article" @default.
• W2897329076 hasAuthorship W2897329076A5012788874 @default.
• W2897329076 hasAuthorship W2897329076A5020227451 @default.
• W2897329076 hasAuthorship W2897329076A5023733267 @default.
• W2897329076 hasAuthorship W2897329076A5027176998 @default.
• W2897329076 hasAuthorship W2897329076A5030404850 @default.
• W2897329076 hasAuthorship W2897329076A5040197178 @default.
• W2897329076 hasAuthorship W2897329076A5040586351 @default.
• W2897329076 hasAuthorship W2897329076A5044668381 @default.
• W2897329076 hasAuthorship W2897329076A5046278307 @default.
• W2897329076 hasAuthorship W2897329076A5048628138 @default.
• W2897329076 hasAuthorship W2897329076A5054056429 @default.
• W2897329076 hasAuthorship W2897329076A5063163135 @default.
• W2897329076 hasAuthorship W2897329076A5071440718 @default.
• W2897329076 hasAuthorship W2897329076A5079400879 @default.
• W2897329076 hasAuthorship W2897329076A5083170859 @default.
• W2897329076 hasBestOaLocation W28973290761 @default.
• W2897329076 hasConcept C121608353 @default.
• W2897329076 hasConcept C126322002 @default.
• W2897329076 hasConcept C126894567 @default.
• W2897329076 hasConcept C143998085 @default.
• W2897329076 hasConcept C144301174 @default.
• W2897329076 hasConcept C167672396 @default.
• W2897329076 hasConcept C188816634 @default.
• W2897329076 hasConcept C196166836 @default.
• W2897329076 hasConcept C203014093 @default.
• W2897329076 hasConcept C2779013556 @default.
• W2897329076 hasConcept C2780192828 @default.
• W2897329076 hasConcept C38180746 @default.
• W2897329076 hasConcept C50382708 @default.
• W2897329076 hasConcept C553184892 @default.
• W2897329076 hasConcept C71924100 @default.
• W2897329076 hasConcept C72563966 @default.
• W2897329076 hasConcept C88879693 @default.
• W2897329076 hasConcept C8891405 @default.
• W2897329076 hasConcept C90924648 @default.
• W2897329076 hasConceptScore W2897329076C121608353 @default.
• W2897329076 hasConceptScore W2897329076C126322002 @default.
• W2897329076 hasConceptScore W2897329076C126894567 @default.
• W2897329076 hasConceptScore W2897329076C143998085 @default.
• W2897329076 hasConceptScore W2897329076C144301174 @default.
• W2897329076 hasConceptScore W2897329076C167672396 @default.
• W2897329076 hasConceptScore W2897329076C188816634 @default.
• W2897329076 hasConceptScore W2897329076C196166836 @default.
• W2897329076 hasConceptScore W2897329076C203014093 @default.
• W2897329076 hasConceptScore W2897329076C2779013556 @default.
• W2897329076 hasConceptScore W2897329076C2780192828 @default.
• W2897329076 hasConceptScore W2897329076C38180746 @default.
• W2897329076 hasConceptScore W2897329076C50382708 @default.
• W2897329076 hasConceptScore W2897329076C553184892 @default.
• W2897329076 hasConceptScore W2897329076C71924100 @default.
• W2897329076 hasConceptScore W2897329076C72563966 @default.
• W2897329076 hasConceptScore W2897329076C88879693 @default.
• W2897329076 hasConceptScore W2897329076C8891405 @default.
• W2897329076 hasConceptScore W2897329076C90924648 @default.
• W2897329076 hasIssue "3" @default.
• W2897329076 hasLocation W28973290761 @default.
• W2897329076 hasOpenAccess W2897329076 @default.
• W2897329076 hasPrimaryLocation W28973290761 @default.
• W2897329076 hasRelatedWork W1979970732 @default.
• W2897329076 hasRelatedWork W2101004633 @default.
• W2897329076 hasRelatedWork W2212921542 @default.
• W2897329076 hasRelatedWork W2335153919 @default.
• W2897329076 hasRelatedWork W2522557386 @default.
• W2897329076 hasRelatedWork W2591601502 @default.
• W2897329076 hasRelatedWork W2793295628 @default.
• W2897329076 hasRelatedWork W2909166520 @default.
• W2897329076 hasRelatedWork W3039910633 @default.
• W2897329076 hasRelatedWork W4320901954 @default.
• W2897329076 hasVolume "102" @default.
• W2897329076 isParatext "false" @default.
• W2897329076 isRetracted "false" @default.
• W2897329076 magId "2897329076" @default.

• next